Meta-analysis of the clinical value of danshen injection and huangqi injection in liver cirrhosis.
Objective. To evaluate the clinical value of Danshen injection and Huangqi injection for the treatment of liver cirrhosis. Methods. The Chinese Biomedical Literature Database (CBM), Chinese Scientific Journals Full-Text Database (VIP), Wanfang Database, China National Knowledge Infrastructure (CNKI), PubMed, and EMBASE database were searched to collect the literatures about the randomized controlled trials involving the treatment of liver cirrhosis with Danshen injection combined with Huangqi injection, and the data analyses were performed using RevMan 4.2 software. Results. A total of 11 studies involving 1086 patients (trials group: 554 cases, control group: 532 cases) were included in this study. Compared with those in control group, the meta-analysis showed-that the total effectiveness rate and the level of serum albumin increased, while serum total bilirubin, alanine transmninase, type III procollagen, hyaluronic acid, laminin, and type-IV collagen decreased in trials group. The Jadad score ranged from 1 to 2 and the funnel plot analysis suggests that publication bias may occur. Conclusions. Danshen injection combined with Huangqi injection may promote the curative efficacy of liver cirrhosis, which is a promising novel treatment approach. The exact outcome needs to perform rigorously designed, multicenter, and large randomized controlled trials.
Department of Radiation Oncology, Changzhou Tumor Hospital Soochow University, Changzhou 213000, China ; Department of Laboratory Medicine, Changzhou Tumor Hospital Soochow University, Changzhou 213000, China.
Changtai
C
Zhu
Hao
H
Cao
Xifa
X
Zhou
Chunlei
C
Dong
Judong
J
Luo
Changsong
C
Zhang
Jinming
J
Liu
Yang
Y
Ling